PHILADELPHIA--(BUSINESS WIRE)--
2018 Veeva R&D Summit -- (NYSE:VEEV) today announced a next-generation cloud application to streamline clinical data management and accelerate study execution. eliminates the need for multiple tools with a single clinical data management application that combines coding, EDC, data cleaning, and reporting. Companies can now have one application that allows them to manage study build through execution and gain a complete and concurrent view of all clinical data within a trial.
“The industry can finally move away from the complex patchwork of systems and integrations that limit the ability to leverage the range of clinical data available throughout the course of a trial,” said Henry Levy, general manager of Veeva Vault CDMS. “Veeva Vault CDMS will provide the key capabilities companies need to bring together all their clinical data so research teams can make faster, more informed decisions.”
Life sciences companies want to use a greater range of data in trials, but today’s EDC systems only manage a limited volume and diversity of clinical data.1 This forces organizations to collect, clean, and analyze data across multiple systems and repositories, restricting visibility and slowing trial execution.
Veeva Vault CDMS delivers on the need for a complete and concurrent view of data throughout the trial with one application for data capture, coding, cleaning, reporting, and management. Companies can now seamlessly bring data together and have daily access to all their clinical data during a trial, instead of waiting weeks or months.
Vault CDMS combines the following capabilities into a single, modern cloud solution:
- , available today, codes medical information with speed and accuracy in Vault CDMS. Streamline medical coding to ensure clinical teams and CROs are using up-to-date, consistent medical terms across all their studies.
- , also available now, maintains and manages all clinical data, including non-CRF data, in one central location. Build, manage, and run studies faster with a modern EDC and significantly improve trial execution.
- Vault Data Workbench, planned for availability in late 2019, will seamlessly bring together all trial data into a consistently formatted data lake for integrated cleaning, reporting, and export. Synchronize data automatically from Vault EDC and Vault Coder. Open APIs are available for a variety of other data sources such as ePRO, medical imaging, labs, and randomization.
Vault CDMS is part of , which also includes , , and , to unify and on a single cloud platform. Veeva’s suite of unified applications provides global visibility of trial processes and data for organizations to easily manage their entire trial portfolio and streamline end-to-end clinical processes.
Vault CDMS is now available with Vault EDC and Vault Coder. Expanded capability with Vault Data Workbench is planned for availability in late 2019. Learn more at .
Additional Information
For more on Veeva Vault CDMS, visit:
Connect
with Veeva on LinkedIn:
Follow
@veevasystems on Twitter:
Like
Veeva on Facebook:
About Veeva Development Cloud
is a unified suite of applications for clinical, regulatory, and quality to help organizations streamline end-to-end product development processes. Veeva has more than 220 clinical customers, 140 regulatory customers, and 180 quality customers using applications to drive greater efficiency and maintain compliance throughout the product lifecycle.2 Learn more at .
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry and other regulated manufacturers. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2018. This is available on the company’s website at under the Investors section and on the SEC’s website at . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
1 Tufts Center for the Study of Drug Development, 2017
eClinical Landscape Study
2 As of fiscal
second quarter ended July 31, 2018
View source version on businesswire.com:
